Orano Med presented a poster at 2022 ASCO annual meeting

Orano Med’s team attended the ASCO annual meeting in June 2022. Jason hurt, MD, CMO of Orano Med, presented data from the AlphaMedix phase I clinical trial. This is the first clinical trial for a 212Pb-targeted alpha-emitter therapy in subjects with neuroendocrine tumors who progressed following prior PRRT. The results open promising perspectives for these patients who have exhausted other therapies.